Table 3.
Clinical annotation for simulated case 1
| Core hospital | Recommended therapy | Considered therapy |
|---|---|---|
| A | Dabrafenib + trametinib | LXH254, TP0903, olaparib, talazoparib + avelumab, BAY1895344, TAK-931 |
| B | Dabrafenib + trametinib | – |
| C | Binimetinib + cetuximab + encorafenib | – |
| D | Dabrafenib + trametinib | – |
| E | Binimetinib + cetuximab + encorafenib, Dabrafenib + trametinib, talazoparib + avelumab, BAY1895344 | – |
| F | Dabrafenib + trametinib, TP0903, BAY1895344 | Trametinib |
| G | – | Dabrafenib + trametinib |
| H | Dabrafenib + trametinib | – |
| I | Binimetinib + cetuximab + encorafenib, Dabrafenib + trametinib, TP0903 | – |
| J | Dabrafenib + trametinib | – |
| K | Binimetinib + cetuximab + encorafenib, dabrafenib + trametinib, PARP inhibitor | – |
– not recommended/considered therapies